-+ 0.00%
-+ 0.00%
-+ 0.00%
EU Clears AstraZeneca's Generalized Myasthenia Gravis Add-on Therapy
Share
Listen to the news
02:14 AM EST, 11/16/2026 (MT Newswires) -- The European Union approved AstraZeneca's (AZN.L, AZN.ST) Klygefa, or gefurulimab, as an add-on to standard therapy to treat adult generalized myasthenia gravis patients who are anti-acetylcholine receptor antibody-positive. The approval, which follows a positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency, was backed by the results of the Prevail phase 3 study, the drugmaker said Monday. The trial met its primary endpoint of showing improvement from baseline in myasthenia gravis activities of daily living total score at week 26, compared with placebo. A clinically meaningful improvement was observed as early as week one, and was sustained through week 26. The drug is already approved in the US, Japan, and other countries for certain adults with generalized myasthenia gravis, while regulatory submissions in China and additional countries are under review.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending